exv10w1






Exhibit 10.1




SUBSCRIPTION AGREEMENT




Columbia Laboratories, Inc.

354 Eisenhower Parkway

Livingston, New Jersey 07039




Gentlemen:



The undersigned (the “Investor”) hereby confirms its agreement with you as follows:




     1. This Subscription Agreement, including the Terms and Conditions For Purchase of Units
attached hereto as Annex I (this “Agreement”), is made as of the date set forth below between
Columbia Laboratories, Inc., a Delaware corporation (the “Company”), and the Investor.



     2. The Company has authorized the sale and issuance to certain investors of up to an aggregate
of 10,900,000 units (the “Units”), each consisting of (i) one share (the “Share,” and collectively,
the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), and (ii) one
warrant (the “Warrant,” and collectively, the “Warrants”) to purchase 0.5 shares of Common Stock
(and the fractional amount being the “Warrant Ratio”), in substantially the form attached hereto as
Exhibit B, subject to adjustment by the Company’s Board of Directors, or a committee
thereof, for a purchase price of $1.08 per Unit (the “Purchase Price”). The Shares issuable upon
exercise of the Warrants are referred to herein as the “Warrant Shares” and, together with the
Units, the Shares and the Warrants, are referred to herein as the “Securities.”



     3. The offering and sale of the Units (the “Offering”) are being made pursuant to (1) an
effective Registration Statement on Form S-3 (including the prospectus contained therein (the “Base
Prospectus”), the “Registration Statement”) filed by the Company with the Securities and Exchange
Commission (the “Commission”), (2) if applicable, certain “free writing prospectuses” (as that term
is defined in Rule 405 under the Securities Act of 1933, as amended (the “Act”)), that have been or
will be filed with the Commission and delivered to the Investor on or prior to the date hereof and
(3) a Prospectus Supplement (the “Prospectus Supplement” and together with the Base Prospectus, the
“Prospectus”) containing certain supplemental information regarding the Securities and terms of the
Offering that will be filed with the Commission and delivered to the Investor (or made available to
the Investor by the filing by the Company of an electronic version thereof with the Commission).



     4. The Company and the Investor agree that the Investor will purchase from the Company and the
Company will issue and sell to the Investor the Units set forth below for the aggregate purchase
price set forth below. The Units shall be purchased pursuant to the Terms and Conditions for
Purchase of Units attached hereto as Annex I and incorporated herein by this reference as
if fully set forth herein. The Investor acknowledges that the Offering is not being underwritten
by the placement agents (the “Placement Agents”) named in the Prospectus Supplement and that there
is no minimum offering amount.



     5. The manner of settlement of the Shares included in the Units purchased by the Investor
shall be determined by such Investor by delivery versus payment (“DVP”) through The Depository
Trust Company (“DTC”) (i.e., the Company shall issue Shares registered in the Investor’s name and
address as set forth below and released by American Stock Transfer and Trust Company, LLC, the
Company’s transfer agent (the “Transfer Agent”) to the Investor through DTC at the Closing directly
to the account(s) at Oppenheimer & Co. Inc. (“Oppenheimer”) identified by the Investor and
simultaneously therewith payment shall be made by Oppenheimer by wire transfer to the Company). NO
LATER THAN ONE (1) BUSINESS DAY AFTER THE EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE
COMPANY, THE INVESTOR SHALL:



 









 






	 	(I)	 	NOTIFY OPPENHEIMER OF THE ACCOUNT OR ACCOUNTS AT OPPENHEIMER TO BE
CREDITED WITH THE SHARES BEING PURCHASED BY SUCH INVESTOR, AND
	 
	 	(II)	 	CONFIRM THAT THE ACCOUNT OR ACCOUNTS AT OPPENHEIMER TO BE CREDITED WITH
THE SHARES BEING PURCHASED BY THE INVESTOR HAVE A MINIMUM BALANCE EQUAL TO THE
AGGREGATE PURCHASE PRICE FOR THE UNITS BEING PURCHASED BY THE INVESTOR.




IT IS THE INVESTOR’S RESPONSIBILITY TO (A) MAKE THE NECESSARY WIRE TRANSFER OR CONFIRM THE
PROPER ACCOUNT BALANCE IN A TIMELY MANNER AND (B) ARRANGE FOR SETTLEMENT BY WAY OF THE
DEPOSIT/WITHDRAWAL AT CUSTODIAN (“DWAC”) SYSTEM OR DVP IN A TIMELY MANNER. IF THE INVESTOR DOES
NOT DELIVER THE AGGREGATE PURCHASE PRICE FOR THE UNITS OR DOES NOT MAKE PROPER ARRANGEMENTS FOR
SETTLEMENT IN A TIMELY MANNER, THE SHARES AND WARRANTS MAY NOT BE DELIVERED AT CLOSING TO THE
INVESTOR OR THE INVESTOR MAY BE EXCLUDED FROM THE OFFERING ALTOGETHER.




     6. The executed Warrant shall be delivered in accordance with the terms thereof.



     7. The Investor represents that, except as set forth below, (a) it has had no position, office
or other material relationship within the past three years with the Company or persons known to it
to be affiliates of the Company, (b) it is not a FINRA member or an Associated Person (as such term
is defined under the FINRA Membership and Registration Rules Section 1011) as of the Closing, and
(c) neither the Investor nor any group of Investors (as identified in a public filing made with the
Commission) of which the Investor is a part in connection with the Offering, acquired, or obtained
the right to acquire, 20% or more of the Common Stock (or securities convertible into or
exercisable for Common Stock) or the voting power of the Company on a post-transaction basis.
Exceptions:



 
(If no exceptions, write “none.” If left blank, response will be deemed to be “none.”)




     8. The Investor represents that it has received (or otherwise had made available to it by the
filing by the Company of an electronic version thereof with the Commission) the Base Prospectus,
dated December 5, 2008, which is a part of the Company’s Registration Statement, the documents
incorporated by reference therein and any free writing prospectus (collectively, the “Disclosure
Package”), prior to or in connection with the receipt of this Agreement. The Investor acknowledges
that, prior to the delivery of this Agreement to the Company, the Investor will receive certain
additional information regarding the Offering, including pricing information (the “Offering
Information”). Such information may be provided to the Investor by any means permitted under the
Act, including the Prospectus Supplement, a free writing prospectus and oral communications.



     9. No offer by the Investor to buy Units will be accepted and no part of the Purchase Price
will be delivered to the Company until the Investor has received the Offering Information and the
Company has accepted such offer by countersigning a copy of this Agreement, and any such offer may
be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the
Company (or a Placement Agent on behalf of the Company) sending (orally, in writing or by
electronic mail) notice of its acceptance of such offer. An indication of interest will involve no
obligation or commitment of any kind until the Investor has been delivered the Offering Information
and this Agreement is accepted and countersigned by or on behalf of the Company.



Number of Units:                                         




-2-









 








Purchase Price Per Unit: $1.08




Aggregate Purchase Price: $                                        




     Please confirm that the foregoing correctly sets forth the agreement between us by signing in
the space provided below for that purpose.



	 	 	 	 	 
	 

	 	Dated as of: October ___, 2009



	 	 
	 

	 	 

	 	 
	 

	 	INVESTOR	 	 

	 
	 

	 	By:  

	 	 
	 

	 	Print Name: 

	 	 
	 

	 	Title: 

	 	 
	 

	 	Address: 
	 	 
	 

	 	 

	 	 






	 	 	 	 	 
	Agreed and Accepted 

this ___ day of October, 2009:



COLUMBIA LABORATORIES, INC.

 	 
	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 



-3-









 






	 	 	 	 	 



ANNEX I




TERMS AND CONDITIONS FOR PURCHASE OF UNITS





     1. Authorization and Sale of the Units. Subject to the terms and conditions of this
Agreement, the Company has authorized the sale of the Units.



     2. Agreement to Sell and Purchase the Units; Placement Agents.



          2.1 At the Closing (as defined in Section 3.1), the Company will sell to the Investor,
and the Investor will purchase from the Company, upon the terms and conditions set forth herein,
the number of Units set forth on the last page of the Agreement to which these Terms and Conditions
for Purchase of Units are attached as Annex I (the “Signature Page”) for the aggregate
purchase price therefor set forth on the Signature Page.




          2.2 The Company proposes to enter into substantially this same form of Subscription Agreement
with certain other investors (the “Other Investors”) and expects to complete sales of Units to
them. The Investor and the Other Investors are hereinafter sometimes collectively referred to as
the “Investors,” and this Agreement and the Subscription Agreements executed by the Other Investors
are hereinafter sometimes collectively referred to as the “Agreements.”




          2.3 Investor acknowledges that the Company has agreed to pay Oppenheimer & Co. Inc. and The
Benchmark Company, LLC (the “Placement Agents”) a fee (the “Placement Fee”) in respect of the sale
of Units to the Investor.




          2.4 The Company has entered into a Placement Agent Agreement, dated October 22, 2009, (the
“Placement Agreement”), with the Placement Agents that contains certain representations,
warranties, covenants and agreements of the Company that may be relied upon by the Investor, which
shall be a third party beneficiary thereof. The Company represents and warrants that a true and
correct copy of the Placement Agreement is attached hereto as Exhibit C and the Company
confirms that all references in the Placement Agreement to “Purchasers” shall include the Investor
and Other Investors. The Company shall promptly notify the Investor of any proposed amendment or
modification to Section 3 (Representations and Warranties of the Company), Section 5 (Further
Agreements of the Company), Section 7 (Conditions to the Obligations of the Placement Agent and the
Purchasers, and the Sale of the Shares), Section 9 (Termination), Section 12 (Successors; Persons
Entitled to Benefit of Agreement) and Section 13 (Survival of Indemnities, Representations,
Warranties, etc.) of the Placement Agreement, which shall require the prior written consent of the
Investor.




          2.5 The Company acknowledges that the only material, non-public information relating to the
Company or its subsidiaries that the Company, its employees or agents has provided to the Investor
in connection with the Offering prior to the date hereof is the existence of the Offering. The
Company confirms that neither it nor any other Person acting on its behalf has provided the
Investor or their agents or counsel with any information, other than information relating to the
Offering, that constitutes or could reasonably be expected to constitute material, nonpublic
information, except as will be disclosed in the Prospectus and the Company’s Form 8-K to be filed
with the Commission in connection with the Offering. The Company understands and confirms that the
Investor will rely on the foregoing representations in effecting transactions in securities of the
Company.




     3. Closings and Delivery of the Units and Funds.



          3.1 Closing. The completion of the purchase and sale of the Units (the “Closing”)
shall occur at a place and time (the “Closing Date”) to be specified by the Company and the
Placement Agents, and of which the Investors will be notified in advance by the Placement Agents,
in accordance with Rule 15c6-1




-4-









 







promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). At
the Closing, (a) the Company shall cause the Transfer Agent to deliver to the Investor the number
of Shares set forth on the Signature Page registered in the name of the Investor or, if so
indicated on the Investor Questionnaire attached hereto as Exhibit A, in the name of a
nominee designated by the Investor, (b) the Company shall cause to be delivered to the Investor a
Warrant to purchase a number of whole Warrant Shares determined by multiplying the number of Shares
(and Units) set forth on the signature page by the Warrant Ratio and rounding down to the nearest
whole number and (c) the aggregate purchase price for the Units being purchased by the Investor
will be delivered by or on behalf of the Investor to the Company.




          3.2 Conditions to the Company’s Obligations. (a) The Company’s obligation to issue
and sell the Units to the Investor shall be subject to: (i) the receipt by the Company of the
purchase price for the Units being purchased hereunder as set forth on the Signature Page and (ii)
the accuracy of the representations and warranties made by the Investor and the fulfillment of
those undertakings of the Investor to be fulfilled prior to the Closing Date.




               (b) Conditions to the Investor’s Obligations. The Investor’s obligation to purchase
the Units will be subject to (i) the delivery by the Company of the Units in accordance with the
provisions of this Agreement, (ii) the accuracy of the representations and warranties made by the
Company and the fulfillment of those undertakings of the Company to be fulfilled prior to the
Closing Date, including without limitation, those contained in the Placement Agreement, and (iii)
the condition that the Placement Agents shall not have: (x) terminated the Placement Agreement
pursuant to the terms thereof or (y) determined that the conditions to the closing in the Placement
Agreement have not been satisfied. The Investor’s obligations are expressly not conditioned on the
purchase by any or all of the Other Investors of the Units that they have agreed to purchase from
the Company. The Investor understands and agrees that, in the event that the Placement Agents in
their sole discretion determine that the conditions to closing in the Placement Agreement have not
been satisfied or if the Placement Agreement may be terminated for any other reason permitted by
such Agreement, then the Placement Agents may, but shall not be obligated to, terminate such
Placement Agreement, which shall have the effect of terminating this Subscription Agreement
pursuant to Section 14 below.



          3.3 Delivery of Funds.




               (a) DWAC Delivery. If the Investor elects to settle the Shares purchased by such
Investor through DTC’s Deposit/Withdrawal at Custodian (“DWAC”) delivery system, no later than
one (1) business day after the execution of this Agreement by the Investor and the Company, the
Investor shall remit by wire transfer the amount of funds equal to the aggregate purchase price for
the Units being purchased by the Investor to the following account designated by the Company and
the Placement Agents pursuant to the terms of that certain Escrow Agreement (the “Escrow
Agreement”), dated as of October 22, 2009, by and among the Company, the Placement Agents and U.S.
Bank National Association (the “Escrow Agent”):


U.S. Bank National Association

ABA # [•]

Account Name: Columbia Laboratories, Inc.

Account Number: [•]




               Such funds shall be held in escrow until the Closing and delivered by the Escrow Agent on
behalf of the Investors to the Company upon the satisfaction, in the sole judgment of the Placement
Agents, of the conditions set forth in Section 3.2(b) hereof. The Placement Agents shall
have no rights in or to any of the escrowed funds, unless the Placement Agents and the Escrow Agent
are notified in writing by the Company in connection with the Closing that a portion of the
escrowed funds shall be applied to the Placement Fee. The Company and the Investor agree to
indemnify and hold the Escrow Agent harmless from and against any and all losses, costs, damages,
expenses and claims (including, without limitation, court costs and reasonable attorneys fees)
(“Losses”) arising under this Section 3.3 or otherwise with respect to the funds held in
escrow pursuant hereto or



-5-









 







arising under the Escrow Agreement, unless it is finally determined that such Losses resulted
directly from the willful misconduct or gross negligence of the Escrow Agent. Anything in this
Agreement to the contrary notwithstanding, in no event shall the Escrow Agent be liable for any
special, indirect or consequential loss or damage of any kind whatsoever (including but not limited
to lost profits), even if the Escrow Agent has been advised of the likelihood of such loss or
damage and regardless of the form of action.



               (b) Delivery Versus Payment through The Depository Trust Company. If the Investor
elects to settle the Shares purchased by such Investor by delivery versus payment through DTC,
no later than one (1) business day after the execution of this Agreement by the Investor and
the Company, the Investor shall confirm that the account or accounts at Oppenheimer to be
credited with the Units being purchased by the Investor have a minimum balance equal to the
aggregate purchase price for the Units being purchased by the Investor.



          3.4 Delivery of Shares.




               (a) DWAC Delivery. If the Investor elects to settle the Shares purchased by such
Investor through DTC’s DWAC delivery system, no later than one (1) business day after the
execution of this Agreement by the Investor and the Company, the Investor shall direct the
broker-dealer at which the account or accounts to be credited with the Shares being purchased by
such Investor are maintained, which broker/dealer shall be a DTC participant, to set up a DWAC
instructing the Transfer Agent to credit such account or accounts with the Shares. Such DWAC
instruction shall indicate the settlement date for the deposit of the Shares, which date shall be
provided to the Investor by Oppenheimer. Simultaneously with the delivery to the Company by the
Escrow Agent of the funds held in escrow pursuant to Section 3.3 above, the Company shall
direct the Transfer Agent to credit the Investor’s account or accounts with the Shares pursuant to
the information contained in the DWAC.



               (b) Delivery Versus Payment through The Depository Trust Company. If the Investor
elects to settle the Shares purchased by such Investor by delivery versus payment through DTC,
no later than one (1) business day after the execution of this Agreement by the Investor and
the Company, the Investor shall notify the Placement Agents of the account or accounts at the
Placement Agents to be credited with the Shares being purchased by such Investor. On the Closing
Date, the Company shall deliver the Shares to the Investor through DTC directly to the account(s)
at Oppenheimer & Co. Inc. identified by the Investor and simultaneously therewith payment shall be
made by the Placement Agents by wire transfer to the Company.



     4. Representations, Warranties and Covenants of the Investor.



     The Investor acknowledges, represents and warrants to, and agrees with, the Company and the
Placement Agents that:



          4.1 The Investor (a) is knowledgeable, sophisticated and experienced in making, and is
qualified to make decisions with respect to, investments in shares presenting an investment
decision like that involved in the purchase of the Units, including investments in securities
issued by the Company and investments in comparable companies, (b) has answered all questions on
the Signature Page and the Investor Questionnaire and the answers thereto are true and correct as
of the date hereof and will be true and correct as of the Closing Date and (c) in connection with
its decision to purchase the number of Units set forth on the Signature Page, has received and is
relying only upon the Disclosure Package and the documents incorporated by reference therein.




          4.2 (a) No action has been or will be taken in any jurisdiction outside the United States by
the Company or the Placement Agents that would permit an offering of the Units, or possession or
distribution of offering materials in connection with the issue of the Securities in any
jurisdiction outside the United States where action for that purpose is required, (b) if the
Investor is outside the United States, it will comply with all applicable laws and regulations in
each foreign jurisdiction in which it purchases, offers, sells or delivers Securities or has in its
possession or distributes any offering material, in all cases at its own expense and (c) the




-6-









 







Placement Agents are not authorized to make and have not made any representation, disclosure
or use of any information in connection with the issue, placement, purchase and sale of the Units,
except as set forth or incorporated by reference in the Base Prospectus or the Prospectus
Supplement.




          4.3 (a) The Investor has full right, power, authority and capacity to enter into this
Agreement and to consummate the transactions contemplated hereby and has taken all necessary action
to authorize the execution, delivery and performance of this Agreement, and (b) this Agreement
constitutes a valid and binding obligation of the Investor enforceable against the Investor in
accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting
parties’ rights generally and except as enforceability may be subject to general principles of
equity (regardless of whether such enforceability is considered in a proceeding in equity or at
law) and except as to the enforceability of any rights to indemnification or contribution that may
be violative of the public policy underlying any law, rule or regulation (including any federal or
state securities law, rule or regulation).




          4.4 The Investor understands that nothing in this Agreement, the Prospectus or any other
materials presented to the Investor in connection with the purchase and sale of the Units
constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or appropriate in
connection with its purchase of Units.




          4.5 Since the date on which the Placement Agents first contacted such Investor about the
Offering, the Investor has not engaged in any transactions in the securities of the Company
(including, without limitation, any Short Sales involving the Company’s securities). Each Investor
covenants that it will not engage in any transactions in the securities of the Company (including
Short Sales) prior to the time that the transactions contemplated by this Agreement are publicly
disclosed. The Investor agrees that it will not use any of the Units acquired pursuant to this
Agreement to cover any short position in the Common Stock if doing so would be in violation of
applicable securities laws. For purposes hereof, “Short Sales” include, without limitation, all
“short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act,
whether or not against the box, and all types of direct and indirect stock pledges, forward sales
contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule
16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and
sales and other transactions through non-U.S. broker dealers or foreign regulated brokers.




     5. Survival of Representations, Warranties and Agreements; Third Party Beneficiary.
Notwithstanding any investigation made by any party to this Agreement or by the Placement Agents,
all covenants, agreements, representations and warranties made by the Company and the Investor
herein will survive the execution of this Agreement, the delivery to the Investor of the Units
being purchased and the payment therefor. The Placement Agents shall be third party beneficiaries
with respect to the representations, warranties and agreements of the Investor in Section 4
hereof.



     6. Notices. All notices, requests, consents and other communications hereunder will be in
writing, will be mailed (a) if within the domestic United States by first-class registered or
certified airmail, or nationally recognized overnight express courier, postage prepaid, or by
facsimile or (b) if delivered from outside the United States, by International Federal Express or
facsimile, and will be deemed given (i) if delivered by first-class registered or certified mail
domestic, three business days after so mailed, (ii) if delivered by nationally recognized overnight
carrier, one business day after so mailed, (iii) if delivered by International Federal Express, two
business days after so mailed and (iv) if delivered by facsimile, upon electric confirmation of
receipt and will be delivered and addressed as follows:




          (a) if to the Company, to:


Columbia Laboratories, Inc.

354 Eisenhower Parkway




-7-









 







Livingston, New Jersey 07039

Attention: Senior Vice President, General Counsel and

Secretary

Facsimile: (973) 994-3001



with a copy (which shall not constitute notice) to:



KAYE SCHOLER LLP

425 Park Avenue

New York, NY 10027

Attention: Adam Golden, Esq.

Facsimile: (212) 836-6573





          (b) if to the Investor, at its address on the Signature Page hereto, or at such
other address or addresses as may have been furnished to the Company in writing.



     7. Changes. This Agreement may not be modified or amended except pursuant to an instrument
in writing signed by the Company and the Investor.



     8. Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and will not be deemed to be part of this Agreement.



     9. Severability. In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions contained herein will not in any way be affected or impaired thereby.



     10. Governing Law. This Agreement will be governed by, and construed in accordance with,
the internal laws of the State of New York, without giving effect to the principles of
conflicts of law that would require the application of the laws of any other jurisdiction.
No legal proceeding may be commenced, prosecuted or continued in any court other than the
courts of the State of New York located in the City and County of New York or in the United
States District Court for the Southern District of New York, which courts shall have
jurisdiction over the adjudication of such matters, and the Company and the Investor each
hereby consent to the jurisdiction of such courts and personal service with respect thereto.
The Company and the Investor each hereby consents to personal jurisdiction, service and
venue in any court in which any legal proceeding arising out of or in any way relating to
this Agreement is brought by any third party against the Company or the Investor. The
Company and the Investor each hereby waive all right to trial by jury in any legal
proceeding (whether based upon contract, tort or otherwise) in any way arising out of or
relating to this Agreement. The Company and the Investor agree that a final judgment in any
such legal proceeding brought in any such court shall be conclusive and binding upon the
Company and the Investor and may be enforced in any other courts in the jurisdiction of
which the Company or the Investor is or may be subject, by suit upon such judgment.



     11. Counterparts. This Agreement may be executed in two or more counterparts, each of which
will constitute an original, but all of which, when taken together, will constitute but one
instrument, and will become effective when one or more counterparts have been signed by each
party hereto and delivered to the other parties. The Company and the Investor acknowledge
and agree that the Company shall deliver its counterpart to the Investor along with the
Prospectus Supplement (or the filing by the Company of an electronic version thereof with
the Commission).



     12. Confirmation of Sale. The Investor acknowledges and agrees that such Investor’s receipt
of the Company’s signed counterpart to this Agreement, together with the Prospectus
Supplement (or the filing by the Company of an electronic version thereof with the
Commission), shall constitute written confirmation of the Company’s sale of Units to such
Investor.



-8-









 





     13. Press Release and Form 8-K. The Company and the Investor agree that the Company shall
on the business day immediately following the date hereof (a) issue a press release
announcing the material terms and conditions of the Offering prior to the opening of the
financial markets in New York City and (b) file a current report on Form 8-K with the
Securities and Exchange Commission including, but not limited to, a form of this Agreement
as an exhibit thereto. From and after the issuance of such press release and Current Report
on Form 8-K, the Company shall have publicly disclosed all material, non-public information
delivered to the Investor by the Company, if any, or any of its officers or directors in
connection with the transactions contemplated hereby. The Company shall not identify any
Investor by name in any press release or public filing, or otherwise publicly disclose any
Investor’s name, without such Investor’s prior written consent, unless required by law or
the rules and regulations of a national securities exchange.



     14. Termination. In the event that the Placement Agreement is terminated by the Placement
Agents pursuant to the terms thereof, this Agreement shall terminate without any further
action on the part of the parties hereto.



-9-









 





Exhibit A




COLUMBIA LABORATORIES, INC.




INVESTOR QUESTIONNAIRE




     Pursuant to Section 3 of Annex I to the Agreement, please provide us with the
following information:



	 	 	 	 	 
	1. The exact name that your Shares and Warrants are to be registered
in. You may use a nominee name if appropriate:
	 	 	 	 
	 
	 	 	 
	 
	2. The relationship between the Investor and the registered holder
listed in response to item 1 above:
	 	 	 	 
	 
	 	 	 
	 
	3. The mailing address of the registered holder listed in response to
item 1 above:
	 	 	 	 
	 
	 	 	 
	 
	4. The Social Security Number or Tax Identification Number of the
registered holder listed in the response to item 1 above:
	 	 	 	 
	 
	 	 	 
	 
	5. Name of DTC Participant (broker-dealer at which the account or
accounts to be credited with the Shares are maintained):
	 	 	 	 
	 
	 	 	 
	 
	6. DTC Participant Number:
	 	 	 	 
	 
	 	 	 
	 
	7. Name of Account at DTC Participant being credited with the Shares:
	 	 	 	 
	 
	 	 	 
	 
	8. Account Number at DTC Participant being credited with the Shares:
	 	 	 	 
	 
	 	 	 





 









 






Exhibit B




Form of Warrant